Strong Top-Line Growth
Total revenue of $376.7M (reported as $377M) in Q1 2026, up ~42% year-over-year, driven by broad-based strength across commercial products and product sales to partners.
Halozyme
· HALO
May 11th, 2026
Summary
- Earnings Call Date:
- 2026-05-11
- Change Since:
- +7.14%
- Next Earnings Date:
- 2026-08-11
Earnings Call Sentiment
PositiveThe call conveyed strong, broad-based commercial and financial momentum: double-digit growth across top-line, royalties, adjusted EBITDA and EPS with reaffirmed 2026 guidance, new $1B buyback, and multiple near- and long-term revenue drivers (ENHANZE expansion, Hypercon, Surf Bio and new CLAs). Key near-term challenges include higher leverage and increased operating expenses from recent acquisitions, and manufacturing/timing execution risk for Hypercon and continued reliance on co-formulation IP to extend royalty duration. On balance, the positive metrics, clear capital allocation plans and pipeline/deal momentum outweigh these operational and timing risks.
Company Guidance
On the call Halozyme reaffirmed its full-year 2026 and 2026–2028 financial guidance, backing total 2026 revenue of $1.71–$1.81 billion (up ~22–30% YoY), royalty revenue of $1.13–$1.17 billion (up ~30–35% YoY) and adjusted EBITDA of $1.125–$1.205 billion (including ~$6 million of planned Hypercon/Surf Bio investment); non‑GAAP diluted EPS is guided to $7.75–$8.25 (does not assume share repurchases). Q1 results that support the outlook included revenue of $376.7 million (+42% YoY), royalty revenue of $240.7 million (+43% YoY), adjusted EBITDA of $229.5 million (+42% YoY), Q1 non‑GAAP EPS of $1.60 (GAAP EPS $1.22), and ENHANZE royalties of ~$241 million in the quarter. Management expects ENHANZE royalties to exceed $1 billion in 2026 (30–35% growth over 2025), projects adjusted EBITDA margins >65% (approaching ~70%) during 2026–2028, and announced a $1 billion share‑repurchase authorization with at least $400 million planned in 2026; net leverage was ~2.5x at quarter end and is expected to decline to ~1.2x by year‑end 2026.
Robust Royalty Revenue
Royalty revenue of $240.7M (reported as $241M) in Q1 2026, up ~43% year-over-year, reflecting continued adoption of ENHANZE-enabled subcutaneous formulations.
High Profitability and EPS Expansion
Adjusted EBITDA of $229.5M (up ~42% YoY) and non-GAAP diluted EPS of $1.60 (vs $1.11 prior year), representing a >40% increase year-over-year; GAAP diluted EPS $1.22 (vs $0.93).
Reaffirmed 2026 Guidance and Multi-Year Outlook
Reaffirmed full-year 2026 guidance: total revenue $1.71B–$1.81B (growth ~22%–30% YoY), royalty revenues $1.13B–$1.17B (30%–35% YoY), adjusted EBITDA $1.125B–$1.205B, and non-GAAP EPS $7.75–$8.25 (excluding potential buyback impact).
ENHANZE Revenue Momentum and Long-Duration Backlog
Company estimates the 10 approved ENHANZE products had generated ~25% of projected royalties by end-2025 and that ~66% of the additional projected royalty revenue remains to come between 2026–2032, implying substantial multi-year upside.
Strong Product-Level Performance
DARZALEX: ~$4B global sales in Q1 (+~18% operational growth) producing $129M royalty revenue (+26% YoY). VYVGART Hytrulo: ~$1.3B global sales (+~63% YoY) producing $46.3M royalties (+119% YoY). PHESGO: CHF686M (~$877M) sales (+27% YoY) producing $30.2M royalties (+25% YoY).
Pipeline and Deal Momentum
Up to 13 additional ENHANZE pipeline products projected to be in development by end-2026 (potential launches 2029+). Signed three new collaboration/licensing agreements in 2026 (including GSK, Vertex, ORKA), and two partners initiated new Phase I ENHANZE studies in Q1 aligned with 6 Phase I starts expected in 2026.
Hypercon and Longer-Term Growth Drivers
Hypercon: first two Phase I clinic starts now projected in H1 2027 with launches targeted 2030–2031; company projects Hypercon could drive ~ $1B in royalty revenue by mid-2030s. Hypercon already has CLAs with 5 companies covering 17 potential targets.
Shareholder Returns and Capital Allocation
Announced a new $1.0B share repurchase authorization with an expectation to buy back at least $400M in 2026 and a projected ~3% annual buyback yield over coming years; capital priorities also include reinvestment in organic programs and deleveraging (plan to retire 2027/2028 notes at maturity).
Operational Leverage and Cash Conversion
Management highlights efficient conversion of revenue to free cash flow, supporting buybacks, debt paydown and disciplined reinvestment in core businesses (ENHANZE, Hypercon, Surf Bio).
Operator
At this time, I would like to welcome everyone to Halozyme's First Quarter 2026 Financial and Operating Results Conference Call. Please note, this event is being recorded. I will now turn the call over to Tram Bui, Halozyme's Vice President of Investor Relations and Corporate Communications. Please go ahead.
Tram Bui
Thank you, operator. Good afternoon, and welcome to our first quarter 2026 financial and operating results conference call. In addition to the press release issued today after the market closed you can find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website. Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Dave Ramsay, our Interim Chief Financial Officer, will review our financial results as well as our outlook. On today's call, we will be making forward-looking statements as outlined on Slide 2. I would also refer you to our SEC filings for a whole list of risks and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed.
Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation. I will now turn the call over to Dr. Helen Torley, and we will start on Slide 3.
Helen Torley
Thank you, Tram, and good afternoon, everyone. We started 2026 with exceptional momentum. The continued strong performance of our currently approved products gives us strong conviction in the 2026 to 2028 financia...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free